Market Research Logo

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2015’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keratoconjunctivitis sicca (Dry Eye), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Keratoconjunctivitis sicca (Dry Eye) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Keratoconjunctivitis sicca (Dry Eye) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Keratoconjunctivitis sicca (Dry Eye) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Keratoconjunctivitis sicca (Dry Eye) Overview
Therapeutics Development
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview
Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies
Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
Allergan Plc
Celsus Therapeutics Plc
Circadian Technologies Limited
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
HanAll Biopharma Co., Ltd.
Herantis Pharma plc.
Huons Co., Ltd.
InSite Vision Incorporated
Kala Pharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Laboratorios Sophia S.A. de C.V.
Lee's Pharmaceutical Holdings Limited
Lipicard Technologies Limited
LTT Bio-Pharma Co., Ltd.
Merck & Co., Inc.
Mimetogen Pharmaceuticals Inc.
Nanomerics Ltd
Neuroptis Biotech
Novaliq GmbH
Ocular Therapeutix, Inc.
OncoNOx ApS
Otsuka Holdings Co., Ltd.
Parion Sciences, Inc.
R-Tech Ueno, Ltd.
RegeneRx Biopharmaceuticals, Inc.
Resolvyx Pharmaceuticals, Inc
Rigel Pharmaceuticals, Inc.
Samjin Pharmaceutical Co., Ltd.
Santen Pharmaceutical Co., Ltd.
Scynexis, Inc.
Seikagaku Corporation
Shire Plc
TearSolutions, LLC.
Vertex Pharmaceuticals Incorporated
Winston Pharmaceuticals, Inc.
Xigen SA
Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AGN-223575 - Drug Profile
AGN-232411 - Drug Profile
AVX-012 - Drug Profile
BRM-421 - Drug Profile
cinhyaluronate sodium - Drug Profile
Cis-Urocanic Acid - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
cyclosporine - Drug Profile
dexamethasone acetate SR - Drug Profile
diclofenac sodium - Drug Profile
diquafosol tetrasodium - Drug Profile
disitertide - Drug Profile
HL-036 - Drug Profile
HU-007 - Drug Profile
ISV-101 - Drug Profile
KBP-7306 - Drug Profile
KeraKlear - Drug Profile
KL-7016 - Drug Profile
Lacripep - Drug Profile
lifitegrast - Drug Profile
LME-636 - Drug Profile
loteprednol etabonate - Drug Profile
NOP-3 - Drug Profile
NOP-5 - Drug Profile
OPX-1 - Drug Profile
OTX-101 - Drug Profile
OX-1001 - Drug Profile
ozagrel - Drug Profile
P-17 - Drug Profile
P-321 - Drug Profile
plastoquinone decyl triphenylphosphonium bromide - Drug Profile
PPL-003 - Drug Profile
PRD-005 - Drug Profile
PRO-148 - Drug Profile
Qi-204 - Drug Profile
R-348 - Drug Profile
rebamipide - Drug Profile
Recombinant Human Nerve Growth Factor - Drug Profile
RGN-259 - Drug Profile
RP-101 - Drug Profile
RU-101 - Drug Profile
ruclosporin - Drug Profile
RX-10005 - Drug Profile
RX-20001 - Drug Profile
SA-001 - Drug Profile
tavilermide hydrochloride - Drug Profile
VGX-100 - Drug Profile
VX-371 - Drug Profile
XG-104 - Drug Profile
ZK-003 - Drug Profile
zucapsaicin - Drug Profile
Keratoconjunctivitis sicca (Dry Eye) - Recent Pipeline Updates
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2015
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Celsus Therapeutics Plc, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Circadian Technologies Limited, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma plc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by R-Tech Ueno, Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Resolvyx Pharmaceuticals, Inc, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Scynexis, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Winston Pharmaceuticals, Inc., H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Keratoconjunctivitis sicca (Dry Eye) Therapeutics - Recent Pipeline Updates, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2015
Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2015
Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report